Polatuzumab vedotin is a CD79b ADC for Large B-cell lymphomas (LBCL) Research
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b for Large B-cell lymphomas (LBCL) Research. CD79b is a surface antigen whose expression is restricted to pre‐B and mature B cells. Besides, CD79b is expressed on nearly all major subtypes of B-cell-derived NHL. While, Large B-cell lymphomas (LBCL) is a fast-growing...
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
Interleukin-1 receptor-associated kinase 4 (IRAK4) is the most upstream kinase in Toll/Interleukin-1 receptor (TIR) signaling. Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling in a variety of myeloid and lymphoid cell types require IRAK4 kinase activity. The MYD88 adaptor protein facilitates the recruitment of IRAK4 to these receptors and...